New startup ideas · Health and bio · Healthcare and bio
startup idea
Titerworks
A shared process model for biologics manufacturing, trained on runs nobody publishes.
Titerworks runs its own farm of several hundred parallel micro-bioreactors and analytics robots, and uses it to train models that predict titer, aggregation and impurity profiles for a new molecule before a pharma company books a pilot suite.
- Software subscription
- Enterprise
- $100B+ market
- Network effects, winner takes most
- Global from day one
4/5
venture judge
48
similar startups, last 2 years (124 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$3,700 · 5 weeks · 15 prospects
For $3,700 and 5 weeks, prove that process development directors at mid-size CDMOs will pay $5,000 and sign a clause returning their run data to a shared model, before a single micro-bioreactor is bought.
Riskiest assumption · Process development directors at mid-size CDMOs will pay before any model exists and will sign a clause returning their run data, including failures, to a model that also serves their direct competitors.
1Focus group: who and where
Director or VP of process development at a mid-size US CDMO (100-2,000 employees) with biologics suites, who ate a failed or re-run bispecific antibody pilot campaign in the past year and answers internally for the margin hit.
where to find 15 · ISPE (International Society for Pharmaceutical Engineering) Boston Area and New Jersey chapter events, where process development leadership shows up monthly; the BioProcess International Conference & Exhibition in Boston this September; Contract Pharma's annual contract manufacturing directory to build the list of mid-size CDMOs with biologics capacity; warm introductions from bioprocess consultants and former colleagues.
2Sell first, build later
A founding design-partner program: a $5,000 blind back-test on three historical runs now, then run designs, media and feed recommendations and failure predictions for one bispecific program starting when the first micro-bioreactor bank is live, under a clause that returns their executed run results to the shared model.
the ask · $5,000 for the back-test, credited against a $50,000 per-program annual subscription.
a real yes · A paid back-test invoice and a countersigned design-partner agreement containing the data-return clause with a dated start count as a yes. Enthusiastic technical feedback, NDA-only conversations and offers to share data for free access do not.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Data-return clause term sheet
$500 · 18 days
Put a 2-page design-partner term sheet, with the data-return clause in bold, in front of 15 process development directors reached through ISPE chapter events, the Contract Pharma directory and warm consultant introductions. Ask each directly: would your legal team sign this clause, and what would they strike? Founder runs every call.
keep going if · 5 of 15 accept the data-return clause in principle and route the term sheet to legal or BD; 14 or 15 refusals is the kill.
2. BPI Boston floor sweep
$1,200 · 5 days
Buy an exhibit hall pass to BioProcess International in Boston and walk the CDMO and bioprocess equipment booths for two days with the term sheet in hand. Book sit-downs with process development and BD leads on the spot and schedule follow-up calls before leaving the hall.
keep going if · 10 booth conversations held; 4 turn into a scheduled term-sheet call within two weeks.
3. Paid blind back-test
$2,000 · 21 days
Offer the 6 warmest directors a $5,000 blind back-test: they send inputs and outcomes for three historical bispecific runs under NDA, the founder and a contracted bioprocess consultant predict titer and aggregation bands from the inputs alone, and both sides score the results on a call within 21 days. Money moves before data does.
keep going if · 2 of 6 pay the $5,000 invoice and send run data.
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$5,000
per prospect, refundable
how · A design-partner agreement signed by the VP of process development or business development, with the $5,000 back-test invoice paid net 15 before any data moves; CDMOs buy through purchase orders and invoices, and a paid invoice forces exactly the legal and data-governance review the whole model depends on. set up: Stripe Invoicing ↗
what it reserves · One of three founding design-partner slots, priority robot-farm capacity for their first molecule, and the $50,000 program price locked for two years.
refund · Refunded in full if predictions and run designs are not delivered within 45 days of their run data arriving.
target · 2 paid agreements from 15 director conversations within 35 days.
Go: build it if
5 of 15 directors accept the data-return clause in principle, 2 of 6 pay the $5,000 back-test, and 2 sign founding design-partner agreements with dated starts within 5 weeks.
Kill: stop if
1 or fewer of 15 directors accepts the data-return clause in any form, or 0 of 6 offered back-tests pay after two follow-ups.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
Your team eats the cost when a bispecific pilot campaign fails and gets re-run, and roughly a third of campaigns do. I am building a prediction model on an owned micro-bioreactor farm: before you book a suite, you get titer, aggregation and impurity predictions plus a run design. The first step is a $5,000 blind back-test - you send three historical runs under NDA, I predict the outcomes from the inputs alone, and we score it together. Worth 20 minutes this week?
landing page
Predict titer and aggregation before you book the pilot suite $5,000 buys a blind back-test on three of your historical runs, credited to a $50,000 founding design-partner year. Request the back-test NDA.
deposit terms
The $5,000 payment, invoiced net 15, reserves one of three founding design-partner slots and locks your program fee at $50,000 per year for two years. It is credited in full to your first program invoice. If we do not deliver your predictions and run designs within 45 days of your data arriving, it is refunded in full.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
67
Idea Score, 0-100 · raw 41.4 x 1.61
Crowded
competition: more crowded than 98% of ideas · headwind x0.51
+5.0
government priorities, secondary (561 matching grants)
Trend
65
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)68
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
- Founders' yes-rate in decks91
100x potential
81
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive38
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were shared, process, model, biologics, manufacturing, trained, nobody, farm.
The idea in full
- What
- Titerworks runs its own farm of several hundred parallel micro-bioreactors and analytics robots, and uses it to train models that predict titer, aggregation and impurity profiles for a new molecule before a pharma company books a pilot suite. Enterprise process development groups at pharma companies and CDMOs subscribe per program and get run designs, media and feed recommendations, and failure predictions; every run they execute, successful or not, is returned to the shared model. It sells to research and process development, before GMP, so nothing needs clearance to ship.
- Why now
- The radar shows the manufacturing and protein layer being funded right now rather than the target layer: AbInitio Bio (yc X26) is building 'The Intelligence layer for Drug Manufacturing', 10x Science (yc W26) is doing next-generation protein characterization, and Ambrosia Biosciences took a $100M Series B on 2026-03-31, which is the size of check that pays for wet lab capacity instead of just software.
- Wedge: first customer and entry point
- Start with one modality, bispecific antibody cell line and media optimization, sold founder to founder to three mid-size CDMOs who lose money on failed pilot campaigns and will trade run data for free capacity on the robot farm.
- Path to 100x
- Biologics manufacturing is a $100B+ spend line and roughly a third of pilot campaigns are re-run; a model that removes one failed campaign per program is worth seven figures a year per program. The mechanism is a data flywheel across competitors who cannot each build a robot farm: every added CDMO makes the predictions better for the next one, and process data is the one asset that does not exist in public literature, so the first company to aggregate it is the only one with it.
- Ceiling
- If each molecule class turns out to be idiosyncratic enough that data does not transfer, the company degrades into a specialised contract lab with revenue tied to robot hours.
- Closest real companies, as the generator saw them
- AbInitio Bio sits in the same layer but as software over a customer's existing plant data; Titerworks generates its own data on owned hardware, so it has predictions on day one for molecules a customer has never run. 10x Science and Scala Biodesign work on the molecule, not on how it is made at scale.
- Main risk
- Pharma process groups refuse to let run data leave their four walls, and the shared model never gets past the founder's own robots.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Process run data exists nowhere public, so the first robot farm aggregating it across CDMOs owns a compounding asset in a $100B+ spend line.
Bootstrapper
1/5
Several hundred parallel micro-bioreactors and analytics robots is a nine-figure buildout before any pharma subscription.
Operator
3/5
A re-run pilot campaign costs seven figures and process groups feel it, but the flywheel needs competing CDMOs to share run data first.
Technologist
5/5
Several hundred owned micro-bioreactors generating process data absent from all public literature is a moat that deepens with every CDMO run returned.
Risk
4/5
Owns its micro-bioreactor farm so predictions exist without customer data, sells pre-GMP where nothing needs clearance, and spreads across multiple CDMOs.
trends
2/5
Why-now is Ambrosia's $100M round and adjacent startups existing, but a biologics data flywheel on owned robots was equally buildable in 2023.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (shared, process, model, biologics, manufacturing, trained, nobody, farm): 124 all-time, 48 from the last two years. Same matching as Idea Check.
Rena Labs enables secure AI operations on private data with TEE data exchange.
We build world models that unlock greater efficiency and automation for the physical industries like manufacturing, retail, and construction.
The autonomous ERP for every manufacturer
CV and robotics to automate quality inspection in fish farms
Infrastructure for AI labs to focus on research.
The shared context layer for recursive companies - your work, your…
Reimagining Hardware Design with multimodal AI
Robots for high skilled labor powering AI infrastructure
Wet lab infrastructure that turns AI experiments into training data.
Titan Foundry provides secure, banking-specific AI models for operations, compliance, and credit analysis.
Reprogramming immunomodulation using AI to cure cancer
Unlock the Speed & Accuracy of Next-Gen Quality Testing
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1596
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
119
opportunities open now in the sector
- Development of a milk analyzing technology for the detection of antibiotic contamination using fluorescence spectroscopy and artificial intelligence.awardhigh relevance
NIH / FDA · SBIR phase I · $200K · posted 2026-09-30
- CAREER: Multimodal Generative AI for Autonomous Biomolecular Design and Accelerated Discoveryawardhigh relevance
National Science Foundation · Info Integration & Informatics · $758K · posted 2026-05-25
- Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunctionawardhigh relevance
NIH / NHLBI · STTR phase I · $606K · posted 2026-09-15
NIH / NIAMS · STTR phase I · $313K · posted 2026-09-15
NIH / NIAMS · SBIR phase II · $306K · posted 2026-08-26
- Implantable Intelligent Engineered System to Enable Virtual Bidirectional Muscle-Prosthesis Mechanical Interaction for Amputeesawardhigh relevance
National Science Foundation · M3X - Mind, Machine, and Motor, Dynamics, Control and System D, Special Initiatives · $809K · posted 2026-08-21
- I-Corps: Translation Potential of a marine-adapted radio frequency identification (RFID) and analytics platform for digital inventory management in shellfish aquacultureawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-19
- GOALI: Machine Learning Enabled Multiscale Modeling Platform and Virtual Sensing Digital Twin for Fatigue in Metals Additive Manufacturing (MAM)awardhigh relevance
National Science Foundation · Mechanics of Materials and Str, AM-Advanced Manufacturing, Special Initiatives · $900K · posted 2026-08-18
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 125 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 441 YC companies here: 6 acquired, 6 shut down, 44 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Network effects, winner takes most
- Market size
- $100B+ market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Founder-led sales
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.